International Inflammatory Bowel Disease Genetics Consortium (IIBDGC)
Research Areas
At a Glance
- Status: Active Consortium
- Year Launched: 2002
- Initiating Organization: IBD Genetics
- Initiator Type: Government
- Disease focus:
Irritable Bowel Disease - Location: North America
Abstract
The International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) is a network of researchers working on the genetics of inflammatory bowel disease (IBD). It has undertaken a number of large-scale genome-wide association studies of Crohn’s disease and ulcerative colitis, which have identified dozens of genomic loci implicated in these diseases. It hopes that this research can be translated into a more complete understanding of the biology of IBD that might lead to improved diagnoses and treatment.
Data Sharing
IIBDGC extends an open invitation to any group to join the consortium. It requests as a minimum high-quality genomic deoxyribonucleic (DNA) and phenotypic information from 500 patients with a confirmed diagnosis of IBD and 500 population-matched healthy controls.
Impact/Accomplishment
IIBDGC collected genetic data from more than 37,000 patients with IBD and discovered 71 new genetic associations, bringing the total number of known associations with IBD to 163, more than for any other human disease. The combination of all this information allowed for new statements about IBD risk that no single locus can tell: IBD is not only genetically similar to other diseases of immunity, but also particularly closely related to certain inflammatory disease such as psoriasis. IBD risk is related not only to changes in the immune system, but also to a particular subset of immune cells and signals. IBD risk is not only related to susceptibility to bacterial infection, but also remarkably strongly connected with susceptibility to the family of bacteria that includes leprosy and tuberculosis.
Links/Social Media Feed
|
Homepage |
Points of Contact
Sponsors & Partners
|
AOU Careggi of Florence |
|
Australia and New Zealand IBD Consortium (ANZIBDC) |
|
Belgian IBD Genetics Consortium |
|
Cervello Hospital, Palermo |
|
Christian-Albrechts-University (Germany) |
|
Dutch Initiative on Crohn and Colitis (ICC) |
|
Flinders Medical Centre (Australia) |
|
Fremantle Hospital (Australia) |
|
IRCCS-CSS Hospital, San Giovannoi Rotondo |
|
Karolinska Institutet |
|
Mater Health Services (Brisbane, Australia) |
|
National Institute of Diabetes, Digestive and Kidney diseases (NIDDK) IBD Genetics Consortium |
|
Orebro University Hospital (Orebro) |
|
Queensland Institute of Medical Research (QIMR) |
|
Royal Adelaide Hospital (RAH) |
|
Royal Brisbane and Women’s Hospital |
|
Townsville Hospital (Australia) |
|
UK IBD Genetics Consortium |
|
University Hospital Careggi of Florence |
|
University Hospital of Lille and Nancy (France) |
|
University Hospital S.-H. (Germany) |
|
University of Otago (New Zealand) |
|
University of Padua |